LRP6 and plasma cell myeloma: In this study, we show increasing Wnt signaling via a novel anti–low‐density lipoprotein receptor‐related protein 6 (LRP6) antibody, which potentiates Wnt1‐class ligand signaling through binding the Wnt receptor LRP6, prevented the development of myeloma‐induced bone loss primarily through preventing bone resorption.